Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel

被引:28
作者
Hochholzer, Willibald [1 ]
Trenk, Dietmar [1 ]
Frundi, Devine [1 ]
Neumann, Franz-Josef [1 ]
机构
[1] Herz Zentrum Bad Krozingen, D-79189 Bad Krozingen, Germany
关键词
clopidogrel; platelet function; non-responder; coronary stenting; PERCUTANEOUS CORONARY INTERVENTION; THERAPY; PRETREATMENT; RESISTANCE; PLACEMENT; ASPIRIN;
D O I
10.1016/j.thromres.2006.02.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The marked interindividual variability in platelet inhibition even after administration of high loading doses of clopidogrel raised the question whether monitoring of antiplatelet effects in patients undergoing percutaneous coronary intervention (PCI) can improve clinical outcome. Established methods for monitoring antiplatelet drug activity such as optical aggregometry and determination of surface protein expression are not suitable for routine bedside testing. Material and methods: We therefore compared the applicability of whole blood impedance aggregometry (20 mu mol/L ADP) and the whole blood bedside ULTEGRA assay with ADP-cartridges (20 mu mol/L) with optical aggregometry in platelet-rich plasma and determination of surface protein expression (P-Selectin and activated GPIIb/IIIa) by flow cytometry. We analyzed samples obtained from 27 patients scheduled for elective PCI who received a loading dose of 600 mg of clopidogret. Blood samples were withdrawn before clopidogrel, before PCI and 24h thereafter. Results: Platelet aggregation assessed by optical aggregometry (20 mu mol/L ADP) declined from 65 +/- 9% (baseline) to 42 +/- 12% (PCI) and 45 +/- 13% (24h; p < 0.01). Expression of surface proteins displayed a similar time course. Platelet aggregation determined by impedance aggregometry decreased from 4.6 +/- 4.0 Omega (baseline) to 0.1 +/- 0.3 Omega (PCI) and 0.5 +/- 1.1 Omega (24h) with no detectable residual platelet aggregation during PCI in 88% of patients. The ULTEGRA assay showed only slight changes after administration of clopidogrel. Correlation analysis between the various assays revealed significant correlations only between optical aggregometry and flow cytometry. Conclusions: The results indicate that both of the whole blood assays cannot substitute for optical aggregometry or determination of surface proteins in the assessment of clopidogrel-induced platelet inhibition. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:285 / 291
页数:7
相关论文
共 11 条
[1]   Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting - The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS) [J].
Bertrand, ME ;
Rupprecht, HJ ;
Urban, P ;
Gershlick, AH .
CIRCULATION, 2000, 102 (06) :624-629
[2]   Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity [J].
Gurbel, PA ;
Bliden, KP ;
Hiatt, BL ;
O'Connor, CM .
CIRCULATION, 2003, 107 (23) :2908-2913
[3]   Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention [J].
Hochholzer, W ;
Trenk, D ;
Frundi, D ;
Blanke, P ;
Fischer, B ;
Andris, K ;
Bestehorn, HP ;
Büttner, HJ ;
Neumann, FJ .
CIRCULATION, 2005, 111 (20) :2560-2564
[4]   Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation - A new drug-drug interaction [J].
Lau, WC ;
Waskell, LA ;
Watkins, PB ;
Neer, CJ ;
Horowitz, K ;
Hopp, AS ;
Tait, AR ;
Carville, DGM ;
Guyer, KE ;
Bates, ER .
CIRCULATION, 2003, 107 (01) :32-37
[5]  
MANI H, 2004, HAMOSTASEOLOGIE, V24, pA85
[6]   Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction [J].
Matetzky, S ;
Shenkman, B ;
Guetta, V ;
Schechter, M ;
Bienart, R ;
Goldenberg, I ;
Novikov, I ;
Pres, H ;
Savion, N ;
Varon, D ;
Hod, H .
CIRCULATION, 2004, 109 (25) :3171-3175
[7]   Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study [J].
Mehta, SR ;
Yusuf, S ;
Peters, RJG ;
Bertrand, ME ;
Lewis, BS ;
Natarajan, MK ;
Maimberg, K ;
Rupprecht, HJ ;
Zhao, F ;
Chrolavicius, S ;
Copland, I ;
Fox, KAA .
LANCET, 2001, 358 (9281) :527-533
[8]   Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement [J].
Müller, I ;
Seyfarth, M ;
Rüdiger, S ;
Wolf, B ;
Pogatsa-Murray, G ;
Schömig, A ;
Gawaz, M .
HEART, 2001, 85 (01) :92-93
[9]   Identification and biological activity of the active metabolite of clopidogrel [J].
Savi, P ;
Pereillo, JM ;
Uzabiaga, MF ;
Combalbert, J ;
Picard, C ;
Maffrand, JP ;
Pascal, M ;
Herbert, JM .
THROMBOSIS AND HAEMOSTASIS, 2000, 84 (05) :891-896
[10]   A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents [J].
Schomig, A ;
Neumann, FJ ;
Kastrati, A ;
Schuhlen, H ;
Blasini, R ;
Hadamitzky, M ;
Walter, H ;
ZitzmannRoth, EM ;
Richardt, G ;
Alt, E ;
Schmitt, C ;
Ulm, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (17) :1084-1089